Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective

Nimer S. Alkhatib a,b,c,d, Abdulaali R. Almutairi e,* , Omar S. Alkhezi f, Osama M. Alfayez g, Majed S. Al Yami h, Omar A. Almohammed i

aAl-Zaytoonah Health Technology Assessment Center (Z-HTA), College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
bCenter for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ, USA
cCollege of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
dMidcapital Healthcare, Amman, Jordan
eDrug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia
fDepartment of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia
gDepartment of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia
hDepartment of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
iDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Abstract

Objectives: To perform a cost of control analysis of glucagon like peptide-1 receptor agonists (GLP1RA) in Saudi Arabia (SA) and determine the economic impact of adopting GLP1RAs.

Methods: A budget impact model that captures the cost of control model was constructed to simulate hypothetical patient on six treatment options: a current mix of 60% liraglutide and 40% dulaglutide, semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide. We estimated the relative amounts of SAR spend to achieve HbA1c targets (≤ 6.5% or < 7.0%). For each treatment option, annual treatment cost, proportion of patients achieving HbA1c targets, and cost to treat major adverse cardiovascular events (MACE) were aggregated to estimate the cost of control per patient per year (CCPPPY) over 5-year horizon (2021–2025). Probabilistic sensitivity analysis (PSA) was performed as a confirmatory analysis.

Results: The CCPPPY to achieve HbA1c ≤ 6.5%<7.0% using current mix, semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide were SAR 17,097/SAR 14,113, SAR 12,889/SAR 11,123, SAR 15,594/SAR 12,892, SAR 19,184/SAR 15,940, SAR 580,211/SAR 380,936, and SAR 246,570/SAR 143,759, respectively. The relative amounts of SAR spend to achieve HbA1c ≤ 6.5%<7.0% relative to 1 SAR on semaglutide in case of adopting current mix, liraglutide, dulaglutide, exenatide, and lixisenatide were SAR 1.42/SAR 1.18, SAR 1.30/SAR 1.07, SAR 1.60/SAR 1.33, SAR 48.33/SAR 31.73, and SAR 20.54/SAR 11.97, respectively. These results were confirmed in the PSA.

Conclusions: Semaglutide 1 mg once weekly was the most economically favorable GLP1RA; associated with the least CCPPPY, and amount of SAR spent to achieve HbA1c of ≤ 6.5%<7.0% versus all other GLP1RAs.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
was US$ 760 billion in 2019 (“International Diabetes Federation Atlas, 9th Edition,” 2019). In addition, the direct cost of T2DM in high-income countries is higher than in low-to middle income countries (Alzaid et al., 2020; “International Diabetes Federation Atlas, 9th Edition,” 2019; Xu et al., 2018).

In high-income countries, healthcare decision makers are trying to reduce the economic burden of T2DM, and its related micro- and macro-vascular complications (Alhowaish, 2013) by considering different measures like adopting innovative and efficacious treatments that showed clinical superiority over the conventional treatments. Glucagon like peptide-1 receptor agonists (GLP1RAs) are innovative T2DM therapies which can reduce bodyweight, optimize HbA1c readings, minimize the risk of hypoglycemia, and control blood pressure and serum lipid levels (Araki et al., 2020; Igarashi et al., 2020). In general, GLP1RAs are effective in reducing the cardiovascular risks in T2DM patients (Zafeiropoulos et al., 2021).

Saudi Arabia (SA) is a high-income country with a gross domestic product (GDP) of US$ 793 billion in 2019 (The World Bank, 2021) and has one of the highest T2DM prevalence globally (Alzaid, 2018). The estimated prevalence of DM among Saudi adults is 18.3% in 2020 (6,443,731 patient) (“International Diabetes Federation Atlas, 9th Edition,” 2019). This prevalence is projected to increase to 20.60% by 2030 (8,454,337 patient) (“International Diabetes Federation Atlas, 9th Edition,” 2019).

From an economic point of view, the World Health Organization (WHO) reported that people diagnosed with diabetes in SA, on average, have medical healthcare expenditures that are ten times higher than what expenditures would be in the absence of diabetes (US$ 3686 versus US$ 380) (Alhowaish, 2013; Mathers et al., 2003; Organization et al., 2005).

In 2014, the Saudi Ministry of Health spent around SAR 25 billion on direct management of all types of DM (Aitken, 2016). For T2DM only, the mean annual economic costs associated with T2DM complications were captured and projected from 2015 to 2025 at SAR 25.7 billion (Aitken, 2016). However, the avoidable complication cost due to the sub-optimal control was estimated at SAR 3.9 billion (Aitken, 2016). In 2014, different measures were taken by the Saudi government to improve patients’ outcomes through delivering novel treatments and self-management technologies (Alzaid, 2018). Liraglutide once daily (QD) was approved by the Saudi Food and Drug Authority (SFDA) in 2014, followed by other GLP1RAs: exenatide twice daily (BID), dulaglutide once weekly (OW), lixisenatide QD, and lastly semaglutide QW in 2020. These GLP1RAs are recommended in health care settings, like in the health system in Saudi Arabia, in which the sub-optimal control of T2DM is frequently seen in DM clinics, and prevalence of overweight is high (36.9% of Saudi population) (Mohan et al., 2020; SS, 2016). Also, antidiabetic treatments are associated with risk of major adverse cardiovascular events (MACE). Such events are associated with high cost that may affect the decision making of antidiabetic treatments.

Although better glycemic control, reduction in patients’ weight, and reduced risk of major adverse cardiovascular events (MACE) remain essential aspects of GLP1RAs, patient access and treatment costs are major limiting factors (Nauck et al., 2021; Stegbaugh et al., 2020). Therefore, economic evaluation of GLP1RAs in SA is needed to inform decisions that can reduce the national burden of T2DM. Such economic evaluation has not been performed yet. In this study, we aimed to perform a budget impact analysis that captures the T2DM-based cost of control analysis per patient per year (CCPPPY) from the Saudi Arabia payer perspective. This cost of control is over 5-year time horizon (2021–2025) in which we captured and compared the costs attributed to the uptake of all approved GLP1RAs in the Saudi market.

2. Methods

2.1. Overview

In this study, we developed a cost of control model that compared the cost of control of a current mix scenario (60% uptake of liraglutide 1.8 mg QD and 40% dulaglutide 1.5 mg QW) with full-uptake scenarios of GLP1RAs in SA: semaglutide 1 mg QW, liraglutide 1.8 mg QD, dulaglutide 1.5 mg QW, exenatide 10 µg BID, and lixisenatide 20 µg QD. This cost of control model was constructed over 5-year time horizon, from 2021 to 2025, and costs were expressed in 2021 Saudi Arabian Riyal (SAR). The cost of control was evaluated for two treatment targets for routine practice: HbA1c ≤ 6.50% and HbA1c < 7.00%. These two targets were recommended by the American Diabetes Association (ADA) (American Diabetes Association, 2021) and the American Association of Clinical Endocrinologists (AACE) (Garber et al., 2020).

This analysis was aimed to capture the 5-year aggregated cost of control for an eligible cohort of T2DM patients in SA. To do so, we used a prevalence-based approach. In which, we multiplied the cost of control per patient per year by the number of eligible T2DM patients in Saudi Arabia. Then, head-to-head cost comparisons and assessment to patient access to GLP1RAs were performed, and relative amounts of SAR to spend to achieve targets of HbA1c were estimated.

2.2. Patient and public involvement

The economic model did not use patient level data. The inputs for the model were obtained from literature and the SFDA website.

2.3. Model inputs

Model inputs used in our analysis are shown in Table 1. The proportions of patients achieving the HbA1c targets, ≤ 6.50% and <7.00%, were obtained from a network metaanalysis (NMA) (Nuhoho et al., 2019). Our analysis used the median proportion for the base case results, reported in this study, and the credible intervals for probabilistic sensitivity analysis (PSA). The rate of MACE for each treatment arm was retrieved from a published network meta-analysis (NMA) (Table1) (Alfayez et al., 2020).

For the cost estimates, the retail prices of GLP1RAs which represent the ceiling prices determined by the SFDA were obtained for all concentrations and retrieved from the SFDA website (Saudi Food and Drug Authority, 2021). The average cost of treating one case of MACE in SA was retrieved from a published article (Mokdad et al., 2015). The estimate was SAR 43,901 per an event, captured in 2014; we applied inflation rate to this estimate based on inflation rates estimated by the world bank and specified for Saudi Arabia (Statista, 2021). That is, this estimate was inflated based on 2021 SAR at SAR 48,464 per one case of MACE. Table 1 shows number of eligible patients to receive GLP1RAs in Saudi Arabia over five years from 2021 to 2025. We provided all statistical numbers and projections to estimate the prevalence of T2DM over the 5-year period (2021 to 2025) in the supplemental material.

As shown in the Table S1, the 5-year population in Saudi Arabia was obtained from published resources (Worldmeter, 2021). The 5-year estimated prevalence of DM (Type 1, Type 2, and other sub types) was obtained from published reports (“International Diabetes Federation Atlas, 8th Edition,” 2018, “International Diabetes Federation Atlas, 9th Edition,” 2019). Given that these estimates were for all types of DM, we aimed to estimate only T2DM population from these estimates by considering that 91% of all DM patients are T2DM as per published reports (“International Diabetes Federation Atlas, 8th Edition,” 2018).
Table 1
Input tables.

| Input | Estimate | Reference |
|-------|----------|-----------|
| Proportion of patients achieving HbA1c targets | HbA1c < 6.50% % (95% CI) | HbA1c < 7.00% % (95% CI) |
| Semaglutide 1 mg QW | 65.30% (50.40–77.50) | 79.80% (69.30–87.40) | Nuhoho, 2019 |
| Liraglutide 1.8 mg QD | 45.80% (33.90–58.30) | 64.60% (53.50–74.40) | Nuhoho, 2019 |
| Dulaglutide 1.5 mg QW | 49.00% (35.20–63.50) | 64.70% (51.90–75.90) | Nuhoho, 2019 |
| Exenatide 10 µg BID | 29.20% (18.30–41.70) | 44.70% (31.30–59.20) | Nuhoho, 2019 |
| Lixisenatide 20 µg QD | 23.50% (15.90–33.70) | 41.10% (31.00–51.90) | Nuhoho, 2019 |
| Current mix1 | 47.08% (34.42–60.38) | 64.64% (52.86–75.00) | Weighted |

MACE rate

| Rate % (95% CI) |
|----------------|
| Semaglutide 1 mg QW | 6.55% (5.41 – 7.86%) |
| Liraglutide 1.8 mg QD | 13.02% (10.07 – 14.02%) |
| Dulaglutide 1.5 mg QW | 12.00% (11.11 – 12.94%) |
| Exenatide 10 µg BID | 11.41% (10.65 – 12.15%) |
| Lixisenatide 20 µg QD | 13.38% (12.19 – 14.64%) |
| Current mix1 | 12.61% (11.69 – 13.59%) |

GLP1RAs in Saudi Arabia

| Retail price SAR2 |
|-------------------|
| Semaglutide (QW): | SAR 381 |
| 0.25 mg (1.5 mg pen), 0.5 mg (1.5 mg pen), 1 mg (3 mg pen) |
| Liraglutide (QD): | SAR 397 |
| 6 mg/ml in 3 ml (2 pens) |
| Dulaglutide (QW): | SAR 504 |
| 0.75 mg, 1.5 mg (4 pens) |
| Exenatide (BID): | SAR 161 |
| 5 mcg, 10 mcg |
| Lixisenatide (QD): | SAR 236 |
| 5 mcg, 10 mcg |
| 10 mcg |
| Cost of MACE management (per case) | SAR 48,464 |
| Number of eligible patients to receive GLP1RA in Saudi Arabia3 | Number of patients (based on 1% of total T2DM cases in SA) |
| 2021 | 58,638 | Estimated |
| 2022 | 60,464 | Estimated |
| 2023 | 62,200 | Estimated |
| 2024 | 63,960 | Estimated |
| 2025 | 65,743 | Estimated |

Abbreviations: QW: once weekly; QD: once daily; BID: twice daily; MACE: major adverse cardiovascular events; GLP1RAs: glucagon like peptide-1 receptor agonists; T2DM: type II diabetes mellitus; CI = credible interval; SA: Saudi Arabia.

1 At assumed uptakes of 60% from liraglutide and 40% from dulaglutide.
2 Probabilistic sensitivity analysis used variations of ±10% of retail estimates.
3 Inflated as per 2021 prices in Saudi Arabia.
4 Estimated from projections that assumed 1% of T2DM prevalence as eligible cohort.

2.4. Assumptions

As shown in Table S2 of the supplemental material, we made three assumptions: first, we assumed that the GLP1RA market uptake involves a current mix of 60% for liraglutide 1.8 mg QD and 40% for dulaglutide 1.5 mg QW based on an expert opinion in Saudi market (Alkhatib N); second, because data on number of eligible patients for GLP1RAs in Saudi Arabia are lacking, we assumed that 1% of total T2DM patients are eligible to receive GLP1RAs; third, based on the International Society for Pharmacoconomics and Outcomes Research (ISPOR) principles of good practice, we assumed that the time horizon for such cost of control analysis is 5 years and no discount rates are applied (Sullivan et al., 2014).

2.5. Analysis

We simulated a single hypothetical patient in each treatment scenario for 1 year of uptake and estimated the cost of control per patient per year (CCPYYY). This was calculated by dividing the combined cost of treating MACE and the annual treatment cost by the proportion of patients achieving targets of HbA1c (≤ 6.50% and < 7.00%). Subsequently, the CCPYYY was multiplied by the eligible number of patients (1% of T2DM patients) specified for the years 2021 to 2025 to estimate the 5-year horizon total cost of control.

We performed head-to-head cost comparisons between treatment options by estimating the difference in the 5-year horizon total cost of control. We estimated the savings achieved (from switching to a lower-cost alternative). Importantly, in case of treatment switching, we assessed the increase in percentage of patient access resulted from switching between treatments. For example, if Y is a treatment with a given cost of SAR 10 and this is less expensive than X with a given cost of SAR 20; if X will be fully replaced with Y, this will yield savings of 100% in the resources which may be relocated to get an additional patient access to treatment Y (two patients can be treated with Y versus one patient can be treated with X at a neutral budget). In other words, this will yield a potential increase in patient access by 100%. Upon this, we estimated the increase in percentage of patient access when complete switching between higher-cost treatments and lower-cost treatments takes place. The calculation for the assessment of patient access relied on the median of 5-year total cost of control to achieve the two HbA1c targets.

We estimated relative amounts of SAR to spend to achieve the two targets of HbA1c. This was performed by estimating the median cost of control to achieve HbA1c ≤ 6.50% and HbA1c < 7.00% for all treatment options; and estimating the relative amount of SAR
which is the quotient of dividing the median of cost of control of a treatment over median of cost of another treatment. The analysis was performed in Microsoft® Excel® 365 MSO supporting visual basic coding for applications. We performed a PSA as a confirmatory analysis using Monte Carlo Simulation and the credible intervals around clinical estimates. The PSA results were reported in the supplemental material.

### 3. Results

The annual cost of GLP1RAs and the CCPPPY to achieve either HbA1c target of HbA1c ≤ 6.50% or HbA1c < 7% are shown in Table 2. Among all GLP1RAs, liraglutide was associated with the lowest annual cost per patient at SAR 4,252 while exenatide was associated with the highest annual cost at SAR 167,807 (Table 2). In terms of the CCPPPY, semaglutide was associated with the lowest cost to bring one patient to HbA1c ≤ 6.50% at SAR 12,889 and SAR 11,123 to achieve HbA1c < 7%. Whereas exenatide was associated with the highest CCPPPY to achieve HbA1c ≤ 6.50% at SAR 380,936 and SAR 380,936 to achieve HbA1c < 7%.

**Table 2**

| GLP1RAs           | Annual cost (per patient) | Cost of control per patient per year (CCPPPY) |
|-------------------|---------------------------|-----------------------------------------------|
|                   |                           | HbA1c ≤ 6.50% | HbA1c < 7.0% |
| Semaglutide 1 mg QW | SAR 6,343                 | SAR 12,889 | SAR 11,123 |
| Liraglutide 1.8 mg QD | SAR 4,252                 | SAR 15,594 | SAR 12,892 |
| Dulaglutide 1.5 mg QW | SAR 6,551                 | SAR 19,184 | SAR 15,940 |
| Exenatide 10 μg BID | SAR 167,807               | SAR 580,211 | SAR 380,936 |
| Lixisenatide 20 μg QD | SAR 56,420                | SAR 246,570 | SAR 143,759 |
| Current mix       | SAR 5,171                 | SAR 17,097 | SAR 14,113 |

Abbreviations: QW: once weekly; QD: once daily; BID: twice daily; GLP1RAs: glucagon like peptide-1 receptor agonists; Current mix: 60% liraglutide and 40% dulaglutide.

**Fig. 1** shows the aggregated 5-year horizon cost of control for the eligible 1% of T2DM patients in SA based on the two HbA1c targets. The lowest aggregated 5-year horizon costs of control to bring 1% of T2DM patients in SA to the targets HbA1c ≤ 6.50% or < 7.00% were observed on treatment with semaglutide at SAR 4,008,395,903, and SAR 3,459,439,832, respectively. The treatment with exenatide was associated with highest costs at SAR 180,448,685,790 and SAR 118,473,332,928, respectively.

As shown in Table 3, the switching from one GLP1RA to another can results in a need for some cost saving. The switching from the exenatide to semaglutide leads to the most cost saving at both HbA1c targets (SAR 176,440,289 for HbA1c ≤ 6.50% / SAR 115,013,893,096 for HbA1c < 7.00%). Whereas the switching from the current mix to liraglutide only leads to the lowest cost saving at both HbA1c targets (SAR 467,440,099 for HbA1c ≤ 6.50% / SAR 379,656,616 for HbA1c < 7.00%). The head-to-head comparisons between the GLP1RAs alternatives were reported based on the 5-year cost of control to achieve either HbA1c targets for the eligible 1% of T2DM patients in SA and the cost differences (saving) from all head-to-head comparisons are shown in Table 3.

Besides the cost saving that could result from switching from one GLP1RA to another, the switching from one GLP1RA to lower-cost alternatives at a neutral budget can result in a corresponding increase in percentages of patient access to these alternatives. The switching from exenatide to semaglutide leads to the largest increases in patients’ access to semaglutide by 4501.77% and 3324.64% to achieve HbA1c ≤ 6.50% and < 7.00%, respectively. Whereas the switching from current mix to liraglutide leads to the lowest increase in patients access to GLP1RAs by 9.64% and 9.47% to achieve HbA1c ≤ 6.50% and < 7.00%, respectively. The results from the head-to-head comparison represented by the increase in patients’ access to GLP1RAs are presented in Table 4.

In our analysis, semaglutide was associated with the least amount of SAR spent to achieve both HbA1c targets. The relative amount spent to achieve HbA1c ≤ 6.50% target relative to SAR 1 spent on once weekly semaglutide ranged between SAR 1.07 if liraglutide was adopted to SAR 31.73 if exenatide was adopted. Likewise, the relative amount spent to achieve HbA1c < 7.00% target relative to SAR 1 spent on once weekly semaglutide ranged between SAR 1.07 if liraglutide was adopted to SAR 31.73 if exen-
semaglutide. Amount spent to achieve target HbA1C relative to 1 SAR spent on once weekly

The increase in patients’ access to GLP1RAs for both HbA1c targets. Exenatide was shown to have the highest CCPPPY and the total 5-year cost of control which resulted in the increase of the patients’ access to other GLP1RAs when exenatide is fully replaced with semaglutide. In this study, used the once weekly semaglutide as a reference option, that is, decisions to switch toward the once weekly semaglutide from other GLP1RAs are informed by the clinical advantages that can be achieved by these agents, but no previous economic evaluation on GLP1RAs has been performed from the Saudi payer perspective. Thus, a transparent analysis to evaluate these GLP1RAs was warranted.

The implications of our findings can be utilized in multiple ways. First, while different GLP1RAs were approved in the SA decision makers are in need for economic models, such as this study, to estimate the financial consequences of adopting these innovative agents. Moreover, patients with T2DM in SA may benefit from the clinical advantages that can be achieved by these agents, but no previous economic evaluation on GLP1RAs has been performed from the Saudi payer perspective. Thus, a transparent analysis to evaluate these GLP1RAs was warranted.

Second, GLP1RAs are available in different ready-to-use formulations, delivery systems, and dosing frequency. Semaglutide and dulaglutide had the advantage of being used once weekly. While liraglutide and lixisenatide are given once daily and exenatide is given twice daily. Studies performed in non-Saudi settings showed that once-weekly formulations of GLP1RAs were associated with better adherence rate and outcomes over once daily formulations (Giorgino et al., 2018; Qiao et al., 2016; Weeda et al., 2021). If this is the case in SA, semaglutide will be even more favorable over other available GLP1RA formulations from economic point of view.

Third, the methods of our model are reproducible to fit specific settings in SA. We suggested that 1% of T2DM population to be treated with GLP1RA. However, decision makers can easily increase or decrease the percentage of T2DM population who can be treated with GLP1RA and get the corresponding CCPPPY. In

Table 3

Head-to-head cost comparison model: the cost difference (saving) for both HbA1c targets ≤ 6.50% or < 7.00%.

| GLP1RAs       | HbA1c ≤ 6.50% | HbA1c < 7.0% |
|---------------|---------------|--------------|
| Semaglutide 1 mg QW | Reference  | Reference     |
| Liraglutide 1.8 mg QD | 1.30         | 1.07          |
| Current mix       | 1.42         | 1.18          |
| Dulaglutide 1.5 mg QW | 1.60         | 1.33          |
| Lixisenatide 20 µg QD | 20.54        | 11.97         |
| Exenatide 10 µg BID | 48.33        | 31.73         |

Abbreviations: QW: once weekly; QD: once daily; BID: twice daily; GLP1RAs: glucagon like peptide-1 receptor agonists; Current mix: 60% liraglutide and 40% dulaglutide.

4. Discussion

Five GLP1RAs were approved between 2014 and 2020 in Saudi Arabia. This study showed that semaglutide 1 mg QW was associated with the best economic outcomes versus other GLP1RAs from the payer perspective. While the annual cost of semaglutide was superseded by liraglutide, semaglutide was associated with the lowest rate of MACE. Therefore, semaglutide had the lowest CCPPPY and the lowest relative amount to spend to achieve either HbA1c targets. Exenatide was shown to have the highest CCPPPY and the total 5-year cost of control which resulted in the increase of the patients’ access to other GLP1RAs when exenatide is fully replaced with one of the other GLP1RAs. The highest increase in the access was observed when exenatide is fully replaced with semaglutide. In this study, used the once weekly semaglutide as a reference option, that is, decisions to switch toward the once weekly semaglutide from other GLP1RAs are informed by the expected increase in patients’ access to semaglutide.

The lack of clinical data in some emerging markets would drive some to extrapolate results of clinical trials in international settings and use international guidelines. Importantly, these international guidelines, while comprehensive, may not be appropriate for some regions; where epidemiology, patient phenotypes, cultural conditions, and socioeconomic status are different (Mohan et al., 2020). When assessing the efficacy or effectiveness of GLP1RAs in SA, data from clinical trials or real-world evidence are lacking. However, international studies showed that these GLP1RAs offer better delivery systems, efficacy in achieving target HbA1C, and weight reduction than other hypoglycemic agents but at higher costs (Giorgino et al., 2018; Prasad-Reddy and Isaacs, 2015; Sun et al., 2015). Considering lacking of country-specific clinical data, decision makers should carefully consider the cost of GLP1RAs when selecting these innovative agents over other conventional treatments; thus, there is a need to construct a balance between the necessity to achieve optimal glycemic control and the affordability and accessibility to GLP1RAs for eligible patients (Mohan et al., 2020).

The implications of our findings can be utilized in multiple ways. First, while different GLP1RAs were approved in the SA decision makers are in need for economic models, such as this study, to estimate the financial consequences of adopting these innovative agents. Moreover, patients with T2DM in SA may benefit from the clinical advantages that can be achieved by these agents, but no previous economic evaluation on GLP1RAs has been performed from the Saudi payer perspective. Thus, a transparent analysis to evaluate these GLP1RAs was warranted.

Second, GLP1RAs are available in different ready-to-use formulations, delivery systems, and dosing frequency. Semaglutide and dulaglutide had the advantage of being used once weekly. While liraglutide and lixisenatide are given once daily and exenatide is given twice daily. Studies performed in non-Saudi settings showed that once-weekly formulations of GLP1RAs were associated with better adherence rate and outcomes over once daily formulations (Giorgino et al., 2018; Qiao et al., 2016; Weeda et al., 2021). If this is the case in SA, semaglutide will be even more favorable over other available GLP1RA formulations from economic point of view.

Third, the methods of our model are reproducible to fit specific settings in SA. We suggested that 1% of T2DM population to be treated with GLP1RA. However, decision makers can easily increase or decrease the percentage of T2DM population who can be treated with GLP1RA and get the corresponding CCPPPY. In
addition, we have used retail prices for GLP1RAs, because tendering prices for public sectors are confidential. However, decision makers from public sectors can adjust the results of this study by applying discounts to retail prices used in this study to make the results more informative for tendering and national procurement commissions in SA.

Fourth, regardless of number of patients being treated, we have highlighted the relative value of one SAR invested on GLP1RAs to achieve two HbA1c targets. Apparently, treating patients to achieve more stringent targets of HbA1c would need more investment. In this study, aiming to achieve stringent HbA1c target of \( \leq 6.50\% \) requires more investment by an average of 37% than achieving HbA1c target of \( < 7.00\% \). This approach of estimating the relative value of 1 unit of a currency was previously suggested and used by Igarashi et al (Igarashi et al., 2020).

Fifth, the results of our study are consistent with the literature. While the study used the cost of control rather than cost-effectiveness analyses, this was mainly due to the lack of country-specific clinical data from SA. A cost-effectiveness analysis was performed using Japanese estimates to compare semaglutide versus dulaglutide, has shown that semaglutide was associated with better clinical-economic outcomes. The amount spent to achieve the targets of HbA1c relative to one Japanese yen (JPY) spent on semaglutide was 1.6 for dulaglutide (Igarashi et al., 2020). This relative value was same as reported in our study despite the purchasing power parity between the SAR to the JPY. Additionally, a cost of control analysis specified for all the available GLP1RAs in the US market, showed that the once weekly semaglutide was ranked second least cost burden over all other GLP1RAs after the oral semaglutide (Hansen et al., 2020); the latter is not yet available in the SA market.

This study has some limitations that needs to be addressed. Data on comparative efficacy and effectiveness of GLP1RAs specified for the SA population were lacking. Therefore, we conservatively generalized the efficacy data collected and summarized from 27 clinical trials in other settings (Nuhoho et al., 2019) to SA population. In addition, data on rates of MACE in SA are lacking. Thus, we used rates for MACE from an NMA of seven randomized clinical trials (Alfayez et al., 2020). However, the results of the NMA can be informative to the economic model used in this study. Also, we assessed the reliability of estimates by performing probabilistic sensitivity analysis that used ranges and confidence intervals reported in the NMAs. Lastly, we have assumed that the current mix of GLP1RA based on experts’ opinion. While this was an assumption, it was validated from clinicians and sales experts in SA. Quality of life associated with all treatment comparators in this study were not included. This is because efforts in literature to estimate utilities in Saudi Arabia were limited to insulin-based formulations (Jarab et al., 2019).

Further studies are needed to confirm the present findings and reveal the uncertainties associated with clinical and economic costs of GLP1RAs in Saudi Arabia. This study can be considered as a preliminary guidance to inform decisions that can reduce the national burden of T2DM on SA. Also, studies that estimate adherence with different GLP1RAs formulations should be performed for the Saudi perspective to better inform clinical and economic decisions for better understanding of patients’ needs and strategizing for the budget efficiently.

5. Conclusion

The findings of this study indicated that the full uptake model of semaglutide 1 mg QW was the most economically favorable model for GLP1RAs in SA. Semaglutide 1 mg QW was associated with the least CCPPPP, and amount of SAR spent to achieve targets HbA1c of \( \leq 6.50\% \) and \( < 7.00\% \) versus all other GLP1RA. Therefore, the full uptake of semaglutide 1 mg QW would improve patients' access to the class of GLP1RAs over the 5-year time horizon.

Declaration of funding

The author (OAA) received a fund from the Researcher Supporting Project number (RSP-2021/77), King Saud University, Riyadh, Saudi Arabia, to support the publication of this article. The funding agency had no role in designing the study, conducting the analysis, interpreting the data or writing the manuscript.

Employment: none

Author contributions

Concept and design: Alkhatib, Almutairi, Alkhezi, Alfayez, Al Yami, Almohammed
Acquisition of data: Alkhatib, Almutairi, Alkhezi, Alfayez, Al Yami
Analysis and interpretation of data: Alkhatib, Almutairi, Alkhezi, Alfayez, Al Yami, Almohammed
Drafting of the manuscript: Alkhatib, Almutairi, Alkhezi, Alfayez, Al Yami, Almohammed
Critical revision of the paper for important intellectual content: Alkhatib, Almutairi, Alkhezi, Alfayez, Al Yami, Almohammed
Administrative, technical, or logistic support: Alkhatib
Supervision: Alkhatib, Almutairi, Almohammed

Personal Financial Interests: none

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors would like to extend their appreciation to King Saud University for funding this work through the Researcher Supporting Project (RSP-2021/77), King Saud University, Riyadh, Saudi Arabia.

“Disclaimer: The contents of this manuscript are solely the authors’ views and may not be understood or quoted as being made on behalf of or reflecting the position of the Saudi Food and Drug Authority.”

Funding/Financial Disclosure

None reported.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jsps.2022.01.018.

References

Aitken, M., 2016. Improving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia Find out more [WWW Document]. URL https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/diabetes-reports/improving-type-2-diabetes-therapy-compliance-and-persistence-in-the-kingdom-of-saudi-arabia.pdf.
Alamzi, T., 2018. mHealth for diabetes self-management in the Kingdom of Saudi Arabia: barriers and solutions. J. Multidiscip. Healthc. 11, 535.
Alfayez, O.M., Almohammed, O.A., Alkhezi, O.S., Almutairi, A.R., Al Yami, M.S., 2020. Indirect comparison of glucagon like peptide-1 receptor agonists regarding
